Guppy Tank: Episode 2
March 1, 2016
Time: 4:00PK - 6:00PM
The partnership between Harvard University's Office of Technology Development and LabCentral brings you the next Guppy Tank. On March 1, two innovative life-science teams will pitch their concepts to a panel of entrepreneurs and investors for constructive, in-depth feedback. Please join us to learn from experts on startup formation and participate in giving audience feedback. Networking reception to follow. Part of a series, this "episode" of Guppy Tank will feature a teams developing cost-effective diagnostic solutions to global health challenges and developing a navigation system that allows the optimization of treatment to individual patients. No 'guppies' will be harmed during this event.
Innovation Team 1: Aldatu Biosciences
Developing cost-effective diagnostic solutions to global health challenges
David Raiser, PhD, CEO and Co-Founder
Aldatu Biosciences is a Cambridge-based biotechnology company developing innovative diagnostic tools based on Pan Degenerate Amplification and Adaptation (PANDAA), a genotyping platform developed by researchers at the Harvard T.H. Chan School of Public Health. Aldatu is committed to commercializing products that address diagnostic challenges in global health, primarily in HIV and other infectious diseases, and that improve both the quality of patient care and healthcare cost-efficiency. Aldatu's lead product, PANDAA HIV6, will be the first HIV drug resistance test designed specifically to meet the clinical and economic constraints of sub-Saharan Africa, offering compelling healthcare cost savings opportunities and improving patient outcomes.
Innovation Team 2: Precision Methods
"Google maps" for Precision Medicine
Isaac Kohane, MD, PhD, Nathan Palmer, PhD, and Andy Bean, PhD
This innovation team from the Department of Biomedical Informatics at Harvard Medical School has developed a transcriptome based "navigator" that allows researchers and clinicians to optimize the treatment of individual patients by easily characterizing patient biopsies and patient-derived iPS cells to diagnose disease and "drive" precision therapeutic options.